IL10 Ig Fusion Protein

Applications

This technology is an IL10 fusion protein that can be used for the treatment of adenocarcinomas that are characterized by the overexpression of the oncogene Pim-1.

Problem Addressed

Cancers of the colon, breast, and prostate collectively account for 20% of cancer deaths in the U.S, therefore, there exists a significant need for new treatment methodologies. This technology provides a potential new treatment paradigm for adenocarcinomas that demonstrate high levels of the oncogene Pim-1. Overexpression of the oncogene Pim-1 has been linked to a subset of colon, breast, and prostate adenocarcinomas, and has been widely proposed as a therapeutic target. The inventors of this technology demonstrate that treatment with IL10 downregulates Pim-1 in an IL6-dependent manner in a mouse model of colon cancer and outline a method for using an IL10 fusion protein as a treatment for Pim-1 positive adenocarcinoma.

Technology

The short circulating plasma half-life of IL10 has previously precluded its use as a therapeutic. A well-established method of increasing circulatory time of proteins involves fusion to the Fc region of IgG. This invention utilizes a human IL10 IgG Fc fusion protein (IL10-Ig) to increase the circulation time of IL10 to more therapeutically-relevant timeframes. This IL10-Ig fusion protein has a half-life at least double that of normal IL10, and the inventors demonstrate an in vivo half-life of >3days in mice. Additionally, treatment of a mouse model of colon adenocarcinoma with a mouse IL10-Ig fusion protein results in normalized Pim-1 levels and an almost complete regression of tumor burden. 

Advantages

  • Increased IL10 plasma circulation time
  • Downregulation of the adenocarcinoma oncogene Pim-1 by an IL10-Ig fusion protein
  • Administration of IL10-Ig fusion protein to mice demonstrated regression of colon adenocarcinoma in vivo